Showing 2631 results
- https://www.novartis.com/news/media-releases/novartis-teams-harvard-develop-next-generation-biomaterial-systems-deliver-immunotherapiesCollaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development…
- https://www.novartis.com/news/media-releases/novartis-announces-changes-executive-committee-support-strategic-prioritiesBertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger…
- https://www.novartis.com/news/media-releases/novartis-kundigt-veranderungen-der-geschaftsleitung-zur-unterstutzung-strategischer-prioritatenBertrand Bodson, Chief Digital Officer, wird in die Geschäftsleitung von Novartis berufen Steffen Lang, Global Head Novartis Technical Operations, wird in die Geschäftsleitung von Novartis berufen…
- https://www.novartis.com/news/media-releases/novartis-annonce-des-changements-au-sein-de-son-comite-de-direction-afin-de-soutenir-ses-priorites-strategiquesBertrand Bodson, Chief Digital Officer, est nommé au Comité de direction de Novartis (Executive Committee of Novartis, ECN) Steffen Lang, Global Head Novartis Technical Operations, est nommé à l'ECN…
- https://www.novartis.com/news/media-releases/novartis-expands-alliance-science-37-advance-virtual-clinical-trials-programNovartis and Science 37 commit to launch up to 10 trials with increasing decentralization over three years, scaling to "site-less" model Agreement builds on our long-standing investment in and…
- https://www.novartis.com/news/media-releases/novartis-xolair-recommended-new-global-chronic-urticaria-guidelineXolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…
- https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-0Shareholders approve 21st consecutive dividend increase to CHF 2.80 (+2%) per share for 2017; representing a 3.6% yield and approximately 67% payout of free cash flow Dr. Joerg Reinhardt…
- https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generaleLes actionnaires approuvent la 21e hausse consécutive du dividende, à CHF 2,80 (+2 %) par action au titre de l'exercice 2017, soit un rendement de 3,6 % et une distribution du free cash-…
- https://www.novartis.com/news/media-releases/novartis-aktionare-genehmigen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-0Aktionäre genehmigen für 2017 die 21. Dividendenerhöhung in Folge auf CHF 2,80 pro Aktie (+2%) - dies entspricht einer Rendite von 3,6% und einer Ausschüttungsquote von rund 67% des Free Cashflow…
- https://www.novartis.com/news/media-releases/novartis-and-pear-therapeutics-develop-digital-therapeutics-patients-schizophrenia-and-multiple-sclerosisNovartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis'…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 264
- › Next page